Sign inJoin
Company / Finance

Merck & Company, Inc.

MRK · NYSE

Merck reported FY2025 revenue of $65.0 billion and 2026 Q1 revenue of $16.3 billion. The thesis depends on Keytruda durability, pipeline conversion, R&D productivity, acquisition discipline and cash conversion.

FollowAdd to WatchlistAsk Question
NYSEMRKCoverage BootstrapMerck & Company, Inc.
Latest ReportMay 19, 2026Merck: Keytruda scale still has to bridge the patent and pipeline testView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
MRK
Clear tags
Latest Thesis

Merck: Keytruda scale still has to bridge the patent and pipeline test

Merck reported FY2025 revenue of $65.0 billion and 2026 Q1 revenue of $16.3 billion. The thesis depends on Keytruda durability, pipeline conversion, R&D productivity, acquisition discipline and cash conversion.

May 19, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Merck & Company, Inc.Keytruda scale still has to bridge the patent and pipeline testMay 19, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Merck: Keytruda scale still has to bridge the patent and pipeline testMerck reported FY2025 revenue of $65.0 billion and 2026 Q1 revenue of $16.3 billion. The thesis depends on Keytruda durability, pipeline conversion, R&D productivity, acquisition discipline and cash conversion.NYSEMay 19, 2026Research reportReadSlides